ABSTRACT
This chapter presents classification & mode of action, indications & dermatological uses, formulations/presentation, dosages & suggested regimens, baseline investigations, considerations monitoring, contraindications, cautions, important drug interactions, adverse effects & their management, use in special situations, and essential patient information of Clofazimine. Clofazimine is a riminophenazine dye and a cornerstone of the multidrug therapy (MDT) of leprosy. Clofazimine is indicated for the treatment of leprosy. Due to its immunosuppressive actions, clofazimine has been used in the management of chronic discoid lupus erythematosus, granulomatous cheilitis, chronic graft-versus-host disease, necrobiosis lipoidica, pyoderma gangrenosum and other neutrophilic dermatoses such as Sweet’s syndrome. Clofazimine is usually prescribed in combination with rifampicin and dapsone. Since 1995, the World Health Organization (WHO) has supplied MDT free of cost for leprosy sufferers in endemic countries. The WHO’s recommended dosage of clofazimine in MDT of multibacillary leprosy is 300 mg once a month and 50 mg daily for the rest of the month for at least 12 months.
